Samsung BioLogics Reports Q2 Revenue of KRW 1.32 Trillion, Up 30% YoY

According to Kiwoom Securities on July 24, Samsung BioLogics (207940) reported second-quarter revenue of KRW 1.3209 trillion, up 30% year-over-year, with operating profit of KRW 586.4 billion, up 23%, matching market consensus. Growth was supported by full-scale operations at existing facilities and favorable exchange rates, despite initial costs from the Songdo Plant 5's performance qualification and the Rockville facility acquisition.

Rockville and Plant 5 are expected to offset anticipated production disruptions from May strikes in the third quarter, with Rockville contributing approximately KRW 100 billion in revenue. Analysts expect fourth-quarter earnings estimates to potentially be raised further, and the acquisition of peptide CDMO firm Polypeptide for KRW 2.7 trillion could improve 2027 outlook.